Document is current
Any future updates will be listed below
-
Authors
Iannuzzo, Gabriella
Calcaterra, Ilenia
Gentile, Marco
Stanzione, Claudia
De Ruberto, Francesca
Di Taranto, Maria Donata
Fortunato, Giuliana
Di Minno, Matteo
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03399786 at ClinicalTrials.govDocuments that mention this clinical trial
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study
https://doi.org/10.1007/s12325-025-03160-4
-
Funding
Funding for this research was provided by:
Università degli Studi di Napoli Federico II
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 27 February 2025
First Online: 2 April 2025
Declarations
:
: Gabriella Iannuzzo, Ilenia Calcaterra, Marco Gentile, Claudia Stanzione, Francesca de Ruberto, Maria Donata di Taranto, Giuliana Fortunato and Matteo Di Minno have nothing to disclose.
: The protocol for ELIPSE HoFH was approved by the relevant institutional review boards or ethics committees (Federico II University Ethics Committee under number 358/18/ESIB8 and compassionate use by the same committee under numbers 379/21, 380/21, 381/21, 382/21, 383/21,384/21, 385/21). The trial was conducted in accordance with the Declaration of Helsinki and its amendments and Good Clinical Practice guidelines. Written informed consent was obtained from each patient.
